<DOC>
	<DOCNO>NCT01994109</DOCNO>
	<brief_summary>This study evaluate efficacy safety MYOBLOC treatment Sialorrhea ( drool ) , symptom many disease condition . MYOBLOC inject directly salivary gland . MYOBLOC show previous trial safely decrease saliva production , thereby demonstrate potential safe effective treatment troublesome sialorrhea .</brief_summary>
	<brief_title>Efficacy Safety Study MYOBLOC® Followed Open-Label Multiple-Treatment With MYOBLOC® Treatment Troublesome Sialorrhea Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Sialorrhea</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>rimabotulinumtoxinB</mesh_term>
	<criteria>Seeking treatment troublesome sialorrhea least 3 month occur secondary disorder relate cause Investigator sit review entire list inclusion criterion potential subject Any known prior exposure botulinum toxin type B , know adverse reaction sensitivity botulinum toxin type A , know sensitivity MYOBLOC solution component . Prior botulinum toxin treatment salivary gland time Investigator sit review entire list exclusion criterion potential subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sialorrhea</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Amyotrophic lateral sclerosis ( ALS )</keyword>
	<keyword>stroke</keyword>
	<keyword>neuroleptic</keyword>
</DOC>